CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Innate Pharma SA is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Innate Pharma SA
117 avenue de Luminy, Bp 30191
Phone: +33 430303030p:+33 430303030 MARSEILLE, 13009  France Ticker: IPHIPH
Business Summary
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
7389 Business services, not elsewhere classified
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer, Chairman of the Executive Board Jonathan E.Dickinson 56 11/1/2024 11/1/2024
Independent Chairwoman of the Supervisory Board IrinaStaatz-Granzer 63 1/1/2024 6/23/2009
Chief Financial Officer, Member of the Executive Committee FredericLombard 49 4/1/2021 4/1/2021
12 additional Officers and Directors records available in full report.

Business Names
Business Name
0EVI
Innate Pharma
Innate Pharma SA
INNTY
IPH
IPHA

General Information
Number of Employees: 168 (As of 6/30/2024)
Outstanding Shares: 80,948,832 (As of 6/30/2024)
Stock Exchange: EPA
Fax Number: +33 430303000


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024